As of May 23, 2025, PTC Therapeutics Inc (PTCT) reports a Net Margin of -45.03%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of PTC Therapeutics Inc's Net Margin
Over recent years, PTC Therapeutics Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -45.03% |
| 2023-12-31 | -66.81% |
| 2022-12-31 | -79.99% |
| 2021-12-31 | -97.27% |
| 2020-12-31 | -115.07% |
This slight upward trend highlights how PTC Therapeutics Inc manages its overall profitability and cost control over time.
Comparing PTC Therapeutics Inc's Net Margin to Peers
To better understand PTC Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| PTC Therapeutics Inc (PTCT) | -45.03% |
| Agios Pharmaceuticals Inc (AGIO) | 1845.92% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| China Biologic Products Holdings Inc (CBPO) | 29.04% |
| ACADIA Pharmaceuticals Inc (ACAD) | 23.64% |
| Amgen Inc (AMGN) | 12.24% |
Compared to its competitors, PTC Therapeutics Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.